HPV Vaccine's Long-Term effects under the microscope in costa rica
NCT ID NCT00867464
First seen Jun 25, 2026 · Last updated Aug 28, 2026 · Updated 5 times
Summary
This study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) years ago, plus unvaccinated controls, to see how well the vaccine protects over time. Researchers are checking for cervical lesions, immune markers, and any increase in infections from other HPV types. The goal is to understand the vaccine's long-term benefits and risks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HPV vaccine (against types 16 and 18)
- What this could lead to
- If successful, this study could confirm how long the HPV vaccine protects against cervical cancer and related diseases, and whether it causes any unexpected shifts in infection patterns.
- What could go wrong
- This is an observational follow-up, not a new treatment test. Results may show waning immunity or increased lesions from other HPV types not covered by the vaccine.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 8,670 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2009
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Young women in Costa Rica who received vaccination against human papillomavirus types 16 and 18 and unvaccinated controls.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women who participated in the Costa Rica Vaccine Trial (CVT) and lived in the Guanacaste province and a few areas of Puntarenas closest to Guanacaste will be eligible for the long-term follow up LTFU study * Women who received the HPV-16/18 vaccine at the start of CVT will be invited for up to 6 years of additional follow-up, and women who were originally in the control arm of CVT and were offered the HPV-16/18 vaccine at crossover will be invited for an additional 2 years of follow-up * A subset of the control arm women who are in the crossover immunogenicity subcohort will be followed the full 6 years * Some women who received HPV vaccination and were not invited into the LTFU protocol (stopped attending their screening visits during CVT, discontinued their study participation during CVT or lived outside the study area) will be invited to participate in the LTFU protocol, particularly those who received an incomplete vaccination schedule * UNVACCINATED CONTROL GROUP: * Born in or between July 1978 and November 1987 * Residents of Guanacaste Province and a few areas of Puntarenas closest to Guanacaste at some point during 2005 * Able to speak/understand Spanish * Apparently mentally competent * Written informed consent obtained prior to enrollment Exclusion Criteria: * History of cervical cancer * History of hysterectomy * Any important medical condition or other criteria that the investigator considers that precludes enrollment * Vaccination with Gardasil or Cervarix will be an exclusionary criterion, but few women are expected to have received these vaccines at the time of enrollment; use of these vaccines after enrollment is not a criterion for study interruption but we plan to collect information on vaccination history so that the few women who report having been vaccinated with one of the HPV vaccines after enrollment can be evaluated separately at analysis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anal carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Agencia Costarricense de Investigaciones Biomédicas (ACIB)
Liberia, Guanacaste Province, 50101, Costa Rica
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dry swabs could simplify HPV screening
- How long do HPV vaccine antibodies last? a 11-Year Follow-Up aims to find out
- Five days of radiation instead of weeks: a new test for head and neck cancer
- Can fewer, stronger radiation doses spare the bowel in gynecologic cancers?
- HPV infections in transgender people: a hidden health gap gets a closer look
- Can heat make radiation more effective against head and neck cancer?